Search

Your search keyword '"Coronel J"' showing total 290 results

Search Constraints

Start Over You searched for: Author "Coronel J" Remove constraint Author: "Coronel J"
290 results on '"Coronel J"'

Search Results

151. Influenza A virus production in a single-use orbital shaken bioreactor with ATF or TFF perfusion systems.

152. Efficient influenza A virus production in high cell density using the novel porcine suspension cell line PBG.PK2.1.

153. Engineering high-gravity fermentations for ethanol production at elevated temperature with Saccharomyces cerevisiae.

154. β-carotene in Obesity Research: Technical Considerations and Current Status of the Field.

155. Point of care HbA 1c level for diabetes mellitus management and its accuracy among tuberculosis patients: a study in four countries.

156. Accuracy of diabetes screening methods used for people with tuberculosis, Indonesia, Peru, Romania, South Africa.

157. Investigating spillover of multidrug-resistant tuberculosis from a prison: a spatial and molecular epidemiological analysis.

159. Convergent evolution and topologically disruptive polymorphisms among multidrug-resistant tuberculosis in Peru.

160. Urine lipoarabinomannan glycan in HIV-negative patients with pulmonary tuberculosis correlates with disease severity.

161. Minimum inhibitory concentration distributions for first- and second-line antimicrobials against Mycobacterium tuberculosis.

162. Dynamics of Cough Frequency in Adults Undergoing Treatment for Pulmonary Tuberculosis.

163. Detecting Mutations in the Mycobacterium tuberculosis Pyrazinamidase Gene pncA to Improve Infection Control and Decrease Drug Resistance Rates in Human Immunodeficiency Virus Coinfection.

164. A quantitative adaptation of the Wayne test for pyrazinamide resistance.

165. dfrA thyA Double Deletion in para-Aminosalicylic Acid-Resistant Mycobacterium tuberculosis Beijing Strains.

166. Participant attributions for global change ratings in unexplained chronic fatigue and chronic fatigue syndrome.

167. Protocol for studying cough frequency in people with pulmonary tuberculosis.

168. Rationing tests for drug-resistant tuberculosis - who are we prepared to miss?

169. Evaluation of a lens-free imager to facilitate tuberculosis diagnostics in MODS.

170. The safety of drug treatments for cervical cancer.

171. Transmission of Multidrug-Resistant and Drug-Susceptible Tuberculosis within Households: A Prospective Cohort Study.

172. Emerging drugs for the treatment of cervical cancer.

173. The Association between Mycobacterium Tuberculosis Genotype and Drug Resistance in Peru.

174. A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer.

175. Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.

176. A field evaluation of the Hardy TB MODS Kit™ for the rapid phenotypic diagnosis of tuberculosis and multi-drug resistant tuberculosis.

177. Extraintestinal helminth infection reduces the development of colitis-associated tumorigenesis.

178. [Implementation of a telediagnostic system for tuberculosis and determination of multi-drug resistance based in the MODS method in Trujillo, Peru].

179. Follow-up consultations for cervical cancer patients in a Mexican cancer center. Comparison with NCCN guidelines.

180. New pharmacotherapy options for cervical cancer.

181. Morphological characterization of Mycobacterium tuberculosis in a MODS culture for an automatic diagnostics through pattern recognition.

182. Chronic fatigue self-management in primary care: a randomized trial.

183. Second-line anti-tuberculosis drug concentrations for susceptibility testing in the MODS assay.

184. Induced sputum MMP-1, -3 & -8 concentrations during treatment of tuberculosis.

185. Uterine sarcomas: review of 26 years at The Instituto Nacional de Cancerologia of Mexico.

186. Cell therapy modulates expression of Tax1-binding protein 1 and synaptotagmin IV in a model of optic nerve lesion.

187. Emerging drugs for cervical cancer.

188. Adenocarcinoma metastatic to the uterine cervix: a case series.

189. Genetic diversity and transmission characteristics of Beijing family strains of Mycobacterium tuberculosis in Peru.

190. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results.

191. Pharmacokinetic evaluation of gemcitabine hydrochloride for the treatment of cervical cancer.

192. F18-FDG-PET/CT in the evaluation of patients with suspected recurrent or persistent locally advanced cervical carcinoma.

193. Inhaled salbutamol plus ipratropium in moderate and severe asthma crises in children.

194. Reliability of the MODS assay decentralisation process in three health regions in Peru.

195. MODS accreditation process for regional reference laboratories in Peru: validation by GenoType® MTBDRplus.

196. Prolonged infectiousness of tuberculosis patients in a directly observed therapy short-course program with standardized therapy.

197. Microscopic observation drug susceptibility assay for tuberculosis screening before isoniazid preventive therapy in HIV-infected persons.

198. Development of low-cost inverted microscope to detect early growth of Mycobacterium tuberculosis in MODS culture.

199. Can the power of mobile phones be used to improve tuberculosis diagnosis in developing countries?

200. Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer.

Catalog

Books, media, physical & digital resources